• Abstract
• Full-Text PDF [1015 KB]

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Katsoulidis, E
• Kaur, S
• Platanias, L
• [+] on Google Scholar
• Katsoulidis, E
• Kaur, S
• Platanias, L
• [+] on PubMed
• Katsoulidis, E
• Kaur, S
• Platanias, L

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Pharmaceuticals 2010, 3(2), 406-418; doi:10.3390/ph3020406

Review

Deregulation of Interferon Signaling in Malignant Cells

Efstratios Katsoulidis, Surinder Kaur and Leonidas C. Platanias*

Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Northwestern University Medical School and Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60611, USA

* Author to whom correspondence should be addressed.

Received: 10 December 2009; in revised form: 28 January 2010 / Accepted: 1 February 2010 / Published: 4 February 2010

(This article belongs to the Special Issue Interferons)

Download PDF Full-Text [1015 KB, uploaded 4 February 2010 11:53 CET]

Abstract: Interferons (IFNs) are a family of cytokines with potent antiproliferative, antiviral, and immunomodulatory properties. Much has been learned about IFNs and IFN-activated signaling cascades over the last 50 years. Due to their potent antitumor effects in vitro and in vivo, recombinant IFNs have been used extensively over the years, alone or in combination with other drugs, for the treatment of various malignancies. This review summarizes the current knowledge on IFN signaling components and pathways that are deregulated in human malignancies. The relevance of deregulation of IFN signaling pathways in defective innate immune surveillance and tumorigenesis are discussed.

Keywords: interferon; signaling pathways; cancer

Article Statistics

Cite This Article